NeuroDerm (NDRM) Reports Q1 Loss of $0.25/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to NeuroDerm (NDRM) Reports Q1 Loss of $0.25/Share

NeuroDerm Announces First Quarter 2016 Financial Results

May 26, 2016 7:32 AM EDT

REHOVOT, Israel, May 26, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2016.

We are pleased with the recent initiation of our long-term safety trial for ND0612L and ND0612H, and remain on track to achieve our development milestones in 2016 for our lead product candidates, with the ultimate goal of providing a more effective, less invasive treatment option for patients suffering from Parkinsons disease, stated Oded... More